ImmunityBio, Inc. Common Stock (IBRX)

Price$8.20

Favorite Metrics

Price vs S&P 500 (26W)217.52%

Price vs S&P 500 (4W)-18.58%

Market Capitalization$8.43B

All Metrics

Book Value / Share (Quarterly)$1.37

P/TBV (Annual)3.09x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)678.62%

Cash Flow / Share (Quarterly)$-0.31

Price vs S&P 500 (YTD)284.75%

Gross Margin (TTM)99.34%

Net Profit Margin (TTM)-310.18%

EPS (TTM)$-0.39

10-Day Avg Trading Volume15.37M

EPS Excl Extra (TTM)$-0.39

Revenue Growth (5Y)184.30%

EPS (Annual)$-0.38

ROI (Annual)-129.86%

Gross Margin (Annual)99.34%

Net Profit Margin (5Y Avg)-61547.29%

Cash / Share (Quarterly)$0.24

Revenue Growth QoQ (YoY)406.95%

ROA (Last FY)-70.01%

Revenue Growth TTM (YoY)668.31%

EBITD / Share (TTM)$-0.22

ROE (5Y Avg)-69.68%

Operating Margin (TTM)-226.00%

Cash Flow / Share (Annual)$-0.31

P/B Ratio56.73x

P/B Ratio (Quarterly)5.04x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)80.73x

Net Interest Coverage (TTM)-1.40x

ROA (TTM)-81.40%

EPS Incl Extra (Annual)$-0.38

Current Ratio (Annual)5.10x

Quick Ratio (Quarterly)4.62x

3-Month Avg Trading Volume31.28M

52-Week Price Return210.48%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.23

P/S Ratio (Annual)74.42x

Asset Turnover (Annual)0.23x

52-Week High$12.43

Operating Margin (5Y Avg)-48537.75%

EPS Excl Extra (Annual)$-0.38

CapEx CAGR (5Y)20.55%

26-Week Price Return226.27%

Quick Ratio (Annual)4.62x

13-Week Price Return154.97%

Total Debt / Equity (Annual)0.01x

Current Ratio (Quarterly)5.10x

Enterprise Value$9,145.639

Revenue / Share Growth (5Y)138.40%

Asset Turnover (TTM)0.26x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-310.37%

Cash / Share (Annual)$0.24

3-Month Return Std Dev172.65%

Net Income / Employee (TTM)$-1

ROE (Last FY)-130.72%

Net Interest Coverage (Annual)-1.40x

EPS Basic Excl Extra (Annual)$-0.38

Receivables Turnover (TTM)5.04x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.39

Receivables Turnover (Annual)5.04x

ROI (TTM)-193.00%

P/S Ratio (TTM)74.42x

Pretax Margin (5Y Avg)-61695.41%

Revenue / Share (Annual)$0.12

Tangible BV / Share (Annual)$1.23

Price vs S&P 500 (52W)175.39%

Year-to-Date Return288.89%

5-Day Price Return5.48%

EPS Normalized (Annual)$-0.38

ROA (5Y Avg)-96.51%

Net Profit Margin (Annual)-310.18%

Month-to-Date Return0.39%

Cash Flow / Share (TTM)$-1.09

EBITD / Share (Annual)$-0.21

Operating Margin (Annual)-226.00%

ROI (5Y Avg)-68.78%

EPS Basic Excl Extra (TTM)$-0.39

P/TBV (Quarterly)3.09x

P/B Ratio (Annual)3.09x

Inventory Turnover (TTM)0.16x

Pretax Margin (TTM)-310.37%

Book Value / Share (Annual)$1.23

Price vs S&P 500 (13W)152.10%

Beta0.17x

Revenue / Share (TTM)$0.11

ROE (TTM)-193.29%

52-Week Low$1.83

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.27

Industry Peers — Biological Products(88)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
IBRXImmunityBio, Inc. Common Stock	74.42x	668.31%	99.34%	—	$8.20
AMGNAmgen Inc	5.20x	9.95%	73.30%	2.93%	$350.16
GILDGilead Sciences Inc	5.71x	2.40%	78.83%	133.64%	$135.87
ARGXargenx SE American Depositary Shares	12.59x	89.56%	150.91%	—	$834.45
BNTXBioNTech SE American Depositary Share	9.06x	-11.81%	84.21%	—	$105.19
BIIBBiogen Inc. Common Stock	2.72x	2.22%	75.69%	-18.77%	$183.34
MRNAModerna, Inc. Common Stock	10.91x	-39.93%	70.32%	—	$54.59
NBIXNeurocrine Biosciences Inc	4.64x	21.45%	98.18%	2.31%	$131.59
EXELExelixis Inc	4.89x	6.85%	96.39%	31.10%	$43.61
TECHBio-Techne Corp.	7.72x	1.64%	66.60%	-20.58%	$60.58
HALOHalozyme Therapeutics, Inc.	5.90x	37.55%	83.62%	22.89%	$69.57

About

ImmunityBio develops immunotherapies for cancer and infectious diseases through its proprietary Cancer BioShield platform, which activates both adaptive and innate immune systems. The platform is anchored by ANKTIVA, an IL-15 superagonist, complemented by adenovirus-vectored vaccines and NK-cell therapies. The company generates the majority of its revenue in the United States, with additional operations in Europe.